Skip to main content
. Author manuscript; available in PMC: 2020 Aug 5.
Published in final edited form as: Clin Cancer Res. 2019 May 29;25(16):4973–4984. doi: 10.1158/1078-0432.CCR-19-0197

Figure 1.

Figure 1.

A and B, Patients with preoperative detectable KRAS ctDNA had decreased RFS and OS. C, Patients with detectable KRAS ctDNA in the immediate postoperative period had decreased RFS. D, Patient with detectable KRAS ctDNA during follow-up had decreased OS.